Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of indolent B-cell non-Hodgkin's lymphoma of 1 of the following subtypes: * Follicular (grade 1, 2, or 3) * Marginal zone (extranodal, nodal, or splenic) * CD20-positive disease * Relapsed or progressive disease after prior anti-neoplastic therapy, as indicated by 1 of the following: * New lesions * Objective evidence of progression of existing lesions * Complete response ≥ 6 months in duration after prior rituximab therapy\* NOTE: \*For patients who were previously treated with a regimen that included rituximab * At least 1 measurable lymph node mass \> 1.5 cm in 2 perpendicular dimensions that has not been irradiated OR that has progressed since prior radiotherapy * No active CNS lymphoma PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 50-100% OR * ECOG 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 50,000/mm\^3 Hepatic * AST and ALT ≤ 3 times upper limit of normal (ULN) * Bilirubin ≤ 2 times ULN Renal * Creatinine ≤ 2 mg/dL OR * Creatinine clearance ≥ 30 mL/min Immunologic * No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins or to any component of rituximab, including polysorbate 80 and sodium citrate dihydrate * No active systemic infection requiring treatment * No history of allergic reaction attributable to compounds containing boron or mannitol Other * No peripheral neuropathy or neuropathic pain ≥ grade 2 * No other malignancy within the past 5 years except completely resected basal cell or squamous cell skin cancer or an in situ malignancy * Previously diagnosed prostate cancer allowed provided the following criteria are met: * T1-2a, N0, M0 disease AND Gleason score ≤ 7 AND prostate specific antigen (PSA) ≤ 10 ng/mL before initial therapy * Treated with definitive curative therapy (i.e., prostatectomy or radiotherapy) within the past 2 years * No clinical evidence of prostate cancer AND undetectable PSA (for prostatectomy patients) or PSA \< 1 ng/mL (for patients who did not undergo prostatectomy) * No serious medical or psychiatric illness that would preclude study participation * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * More than 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g., ibritumomab tiuxetan or iodine I 131 tositumomab) * More than 4 weeks since prior rituximab, alemtuzumab, or other unconjugated therapeutic antibody * No concurrent prophylactic bone marrow growth factors (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], or epoetin alfa) during course 1 of study therapy Chemotherapy * More than 6 weeks since prior nitrosoureas * No concurrent cisplatin Endocrine therapy * No concurrent corticosteroids (e.g., dexamethasone) except prednisone ≤ 15 mg/day or equivalent for adrenal insufficiency Radiotherapy * See Disease Characteristics * See Biologic therapy * More than 3 weeks since prior radiotherapy * No concurrent radiotherapy Surgery * More than 2 weeks since prior major surgery Other * Recovered from all prior therapy * No prior bortezomib * More than 3 weeks since prior antineoplastic therapy * More than 3 weeks since prior experimental therapy * No other concurrent antineoplastic therapy * No other concurrent investigational agents * Concurrent participation in a non-treatment study allowed provided it does not interfere with participation in this study